期刊文献+

E2F陷阱DNA对人肺癌细胞中stathm in mRNA表达的影响及促进肿瘤细胞凋亡的作用

Apoptosis induction and stathmin expression by E2F decoy DNA of Human Lung Cancer cell line A549
下载PDF
导出
摘要 目的:观察转录因子E2F陷阱DNA对stathmin的表达影响及抑制肿瘤细胞增生情况。方法:采用脂质体LipofectamineTM2000将E2F Decoy ODNs转染入人肺癌A549细胞中,用RT-PCR检测转染细胞中stathmin基因mRNA表达水平变化,通过细胞生长曲线观察转染细胞的增殖能力,Tunel法观察转染细胞凋亡情况。结果:E2F Decoy ODNs被成功转染入肿瘤细胞中,RT-PCR检测结果显示实验组stathmin mRNA表达水平明显低于对照组,而且显著抑制了A549细胞的增殖,空白对照组无明显变化,Tunel凋亡染色可见凋亡细胞。结论:E2F Decoy ODNs能特异性下调stathmin mRNA表达,明显抑制A549细胞的增殖,为肿瘤的基因治疗提供了新的手段。 Objective: To investigate the inhibition effect of E2F decoy Oligodeoxynucleotides (E2F decoy ODNs) in dumbbell shape on mRNA expression of op18 gene and the proliferation of the tumor cells. Methods: E2F decoy ODNs were transfected into A549 cells mediated by lipofectamineTM 2000. The proliferative activity of tumor cells was analyzed by cell grow curve assay, and mRNA expression of op18 gene in tumor cells was detected by RT - PCR. Results: E2F decoy ODNs could be successfully tranfected into tumor cells. The proliferation of tumor cells was inhibited markedly by E2F decoy ODNs. The results of RT - PCR indicated that E2F decoy ODNs decreased expression of op18 gene in tumor cells. Morphologic analysis showed marked increase in apoptosis identified by tunel staining. Conclusion: E2F decoy ODNs may sequence specifically inhibit the activity of transcription factor E2F, inhibit the proliferation of A549 ceils, decrease expression of opl 8 gene, and might be a potential new strategy for tumor gene therapy.
出处 《现代肿瘤医学》 CAS 2007年第4期485-487,共3页 Journal of Modern Oncology
关键词 E2F陷阱DNA 转录因子 增殖 A549细胞 基因治疗 E2F decoy ODNs transcription factors proliferation A549 cells gene therapy
  • 引文网络
  • 相关文献

参考文献10

  • 1Ichael J Mann,Victor J1 Dzaul.Therapeutic applications of transcription factor decoy oligonucleotidesl[J].J Clin Invest,2000,106 (9):10712~10751.
  • 2Ryuichi Morishital.Application of transcription factor "decoy"strategy as means of gene therapy and study of gene expression incardiovascular disease[J].Cir Res,1998,82:10232 ~ 10281.
  • 3Sherr CJ.Cancer cell cycles[J].Science,1996,274:16722 ~16771.
  • 4Nimjee SM,Rusconi CP,Sullenger BA.Aptamers:an emerging class of therapeutics[J].Annu Rev Med,2005,56:555 ~ 583.
  • 5Rubin CI,Atweh GF.The role of op18 in the regulation of the cell cycle[J].J Cell Biochem,2004,93(2):242 ~250.
  • 6Polzin RG,Benlhabib H,Trepel J,et al.E2F sites in the Op18promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M[J].Gene,2004,(341):209 ~218.
  • 7Ahn JD,Morishita R,Kaneda Y.Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia[J].Gene Ther,2002,9 (24):1682 ~ 1692.
  • 8Lim CS,Jabrane-Ferrat N,Fontes JD,et al.Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys[J].Nucleic Acids Res,1997,25(3):575 ~581.
  • 9Hosoya T,Takeuchi H.Sequenco-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides[J].FEBS Lett,1999,461(3):136 ~ 140.
  • 10Hugh Cam,Brian David.Emerging roles for E2F:Beyond the G1/S transition and DNA replication[J].Cancer Cell,2003,3:311.
;
使用帮助 返回顶部